Sharma, M., Lathers, D., Johnson, M., Luke, J., Puzanov, I., Curti, B., Chen, C., El-Khoueiry, A., Henick, B., Callahan, M., Sznol, M., Patel, S., Wilson, D., Ricker, M., Cao, L., Jayaraman, P., Che, J., Peng, L., Feltquate, D., … Tolcher, A. (2022). 772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01). Regular and Young Investigator Award Abstracts, A803–A803. https://doi.org/10.1136/jitc-2022-sitc2022.0772
Subjects:
Engineering Bacteria for Cancer Treatment
(OpenAlex Topic)
Glycosylation in Health and Disease
(OpenAlex Topic)
Therapeutic Antibodies: Development, Engineering, and Applications
(OpenAlex Topic)
Publication Type:
Article
Unique ID:
10.1136/jitc-2022-sitc2022.0772
Journal:
Publication Date:
Data Source:
OpenAlex
Source Link: